Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S.

Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

PMID:
30326787
2.

COMPETITIVE TESTING THE WHO 2010 VS THE WHO 2017 GRADING OF PANCREAS NEUROENDOCRINE NEOPLASIA: DATA FROM A LARGE INTERNATIONAL COHORT STUDY.

Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Büchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen C, Inzani F, Jann H, Komminoth P, Knigge U, Landoni L, La Rosa S, Lawlor R, Luong T, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt AM, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee W, Zerbi A, Falconi M.

Neuroendocrinology. 2018 Oct 9. doi: 10.1159/000494355. [Epub ahead of print]

PMID:
30300897
3.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26.

PMID:
29700053
4.

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.

Inno A, Di Noia V, Martini M, D'Argento E, Di Salvatore M, Arena V, Schinzari G, Orlandi A, Larocca LM, Cassano A, Barone C.

Pathol Oncol Res. 2018 Mar 20. doi: 10.1007/s12253-018-0404-x. [Epub ahead of print]

PMID:
29557085
5.

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?

Rossi S, Di Noia V, Tonetti L, Strippoli A, Basso M, Schinzari G, Cassano A, Leone A, Barone C, D'Argento E.

Future Oncol. 2018 Apr;14(10):919-926. doi: 10.2217/fon-2017-0499. Epub 2018 Mar 12.

PMID:
29528255
6.

Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.

Lorusso M, Inzani F, Castaldi P, Menghi R, Schinzari G, Rindi G, Rufini V.

Pancreas. 2018 Apr;47(4):e20-e22. doi: 10.1097/MPA.0000000000001012. No abstract available.

PMID:
29521949
7.

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium.

Schinzari G, Rossi E, Pierconti F, Garufi G, Monterisi S, Strippoli A, D'Argento E, Cassano A, Barone C.

Oncotarget. 2018 Jan 11;9(9):8765-8771. doi: 10.18632/oncotarget.24162. eCollection 2018 Feb 2.

8.

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconicini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F.

Pancreatology. 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12.

PMID:
29361429
9.

The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration.

Pierconti F, Rossi ED, Straccia P, Fadda G, Larocca LM, Bassi PF, Sacco E, Schinzari G.

Cancer Cytopathol. 2018 Mar;126(3):200-206. doi: 10.1002/cncy.21957. Epub 2018 Jan 23.

PMID:
29360198
10.

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies.

Rossi S, Cassano A, Strippoli A, Schinzari G, D'Argento E, Basso M, Barone C.

Drugs Context. 2017 Nov 8;6:212506. doi: 10.7573/dic.212506. eCollection 2017.

11.

Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.

Schinzari G, Rossi E, Cassano A, Dadduzio V, Quirino M, Pagliara M, Blasi MA, Barone C.

Melanoma Res. 2017 Dec;27(6):591-595. doi: 10.1097/CMR.0000000000000401.

PMID:
29076951
12.

Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.

Schinzari G, Monterisi S, Pierconti F, Nazzicone G, Marandino L, Orlandi A, Racioppi M, Cassano A, Bassi P, Barone C, Rossi E.

Anticancer Res. 2017 Nov;37(11):6453-6458.

PMID:
29061832
13.

RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer.

Rossi E, Bagalà C, Inzani F, Leoncini E, Brunelli C, Lanza P, Basso M, Mattiucci GC, Cassano A, Rindi G, Barone C, Schinzari G.

In Vivo. 2017 Sep-Oct;31(5):833-840.

14.

First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen).

Schinzari G, Rossi E, Mambella G, Strippoli A, Cangiano R, Mutignani M, Basso M, Cassano A, Barone C.

Anticancer Res. 2017 Sep;37(9):5193-5197.

PMID:
28870954
15.

Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Chiloiro S, Lanza F, Bianchi A, Schinzari G, Brizi MG, Giampietro A, Rufini V, Inzani F, Giordano A, Rindi G, Pontecorvi A, De Marinis L.

Endocrine. 2018 May;60(2):362-367. doi: 10.1007/s12020-017-1327-0. Epub 2017 May 31.

PMID:
28567607
16.

DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.

Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D'Argento E, Strippoli A, Schinzari G, Iezzi R, Cassano A, Barone C.

Future Oncol. 2017 Apr 25. doi: 10.2217/fon-2017-0025. [Epub ahead of print]

PMID:
28440086
17.

Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.

Quirino M, Rossi S, Schinzari G, Basso M, Strippoli A, Cassano A, Barone C.

Medicine (Baltimore). 2017 Apr;96(16):e6522. doi: 10.1097/MD.0000000000006522.

18.

Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?

Rossi S, Basso M, Strippoli A, Schinzari G, D'Argento E, Larocca M, Cassano A, Barone C.

Clin Colorectal Cancer. 2017 Dec;16(4):264-274. doi: 10.1016/j.clcc.2017.03.015. Epub 2017 Mar 24. Review.

PMID:
28412137
19.

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.

Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C.

Oncotarget. 2017 Mar 7;8(10):16887-16898. doi: 10.18632/oncotarget.14810.

20.

Erratum to: From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

D'Argento E, Rossi S, Schinzari G, Strippoli A, Basso M, Cassano A, Barone C.

Curr Treat Options Oncol. 2016 Dec;17(12):65. No abstract available.

PMID:
27995578
21.

From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

D'Argento E, Rossi S, Schinzari G, Strippoli A, Basso M, Cassano A, Barone C.

Curr Treat Options Oncol. 2016 Dec;17(12):59. Review. Erratum in: Curr Treat Options Oncol. 2016 Dec;17 (12 ):65.

PMID:
27766545
22.

Gastrointestinal stromal tumors (GISTs) and second malignancies: A novel "sentinel tumor"? A monoinstitutional, STROBE-compliant observational analysis.

Rodriquenz MG, Rossi S, Ricci R, Martini M, Larocca M, Dipasquale A, Quirino M, Schinzari G, Basso M, D'Argento E, Strippoli A, Barone C, Cassano A.

Medicine (Baltimore). 2016 Sep;95(38):e4718. doi: 10.1097/MD.0000000000004718.

23.

Are TKIs favourable for the elderly with non-small-cell lung cancer?

Rossi S, D'Argento E, Schinzari G, Dadduzio V, Di Noia V, Cassano A, Barone C.

Oncotarget. 2016 Jul 26;7(30):46871-46877. doi: 10.18632/oncotarget.9389.

24.

ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.

Strippoli A, Rossi S, Martini M, Basso M, D'Argento E, Schinzari G, Barile R, Cassano A, Barone C.

Oncotarget. 2016 Jun 7;7(23):35159-68. doi: 10.18632/oncotarget.9063.

25.

Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.

Rossi S, Schinzari G, Basso M, Strippoli A, Dadduzio V, D'Argento E, Cassano A, Barone C.

Future Oncol. 2016 May;12(10):1299-307. doi: 10.2217/fon-2015-0065. Epub 2016 Mar 21. Review.

PMID:
26996100
26.

KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.

Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, Orlandi A, Cerchiaro E, Schinzari G, Cassano A, Martini M, Barone C.

Mol Diagn Ther. 2016 Feb;20(1):65-74. doi: 10.1007/s40291-015-0178-8.

PMID:
26610798
27.

Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.

Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, D'Argento E, Cassano A, Schinzari G, Barone C.

Clin Breast Cancer. 2015 Oct;15(5):307-12. doi: 10.1016/j.clbc.2015.03.010. Epub 2015 Mar 25. Review.

PMID:
25922284
28.

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, Ortega C, Guida FM, Silletta M, Schinzari G, Verzoni E, Modica D, Crucitti P, Rauco A, Felici A, Ballatore V, Cascinu S, Tonini G, Carteni G, Russo A, Santini D.

PLoS One. 2015 Apr 17;10(4):e0120427. doi: 10.1371/journal.pone.0120427. eCollection 2015.

29.

Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.

Schinzari G, Monterisi S, Signorelli D, Cona MS, Cassano A, Danza F, Barone C.

Tumori. 2014 Nov-Dec;100(6):e298-300. doi: 10.1700/1778.19304.

PMID:
25688515
30.

Targeted therapy in advanced gastric carcinoma: the future is beginning.

Schinzari G, Cassano A, Orlandi A, Basso M, Barone C.

Curr Med Chem. 2014;21(8):1026-38. Review.

PMID:
24304282
31.

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.

Basso M, Strippoli A, Orlandi A, Martini M, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A, Larocca LM, Barone C.

Br J Cancer. 2013 Jan 15;108(1):115-20. doi: 10.1038/bjc.2012.526. Epub 2012 Nov 22.

32.

Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.

Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, Quaranta D, Tonali PA, Barone C.

Cancer Chemother Pharmacol. 2011 May;67(5):1179-87. doi: 10.1007/s00280-010-1466-y. Epub 2010 Sep 25.

PMID:
20872144
33.

Temsirolimus: is improved survival the correct expression of drug activity?

Basso M, Cassano A, Schinzari G, Barone C.

Oncologist. 2010;15(7):790-1; author reply 792. doi: 10.1634/theoncologist.2010-0099. No abstract available.

34.

Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.

Rossi B, Schinzari G, Maccauro G, Scaramuzzo L, Signorelli D, Rosa MA, Fabbriciani C, Carlo B.

BMC Musculoskelet Disord. 2010 Feb 16;11:34. doi: 10.1186/1471-2474-11-34.

35.

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA.

Br J Cancer. 2009 Oct 20;101(8):1261-8. doi: 10.1038/sj.bjc.6605319. Epub 2009 Sep 22.

36.

Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.

Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.

Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.

PMID:
19152342
37.

7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study.

Persiani R, Rausei S, Pozzo C, Biondi A, Barone C, Cananzi FC, Schinzari G, D'Ugo D.

Ann Surg Oncol. 2008 Aug;15(8):2146-52. doi: 10.1245/s10434-008-9982-2. Epub 2008 Jun 10.

PMID:
18543037
38.

A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance.

Basso M, Cassano A, Modoni A, Spada D, Trigila N, Quirino M, Schinzari G, Barone C.

Eur J Clin Pharmacol. 2008 Jul;64(7):739-41. doi: 10.1007/s00228-008-0474-x. Epub 2008 Mar 19. No abstract available.

PMID:
18350285
39.

Role of chemotherapy in malignant thymoma.

Valente M, Schinzari G, Ricciotti A, Barone C.

Ann Ital Chir. 2007 Sep-Oct;78(5):377-80. Review.

PMID:
18338542
40.

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.

Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D'Argento E, Trigila N, Astone A, Pozzo C.

Br J Cancer. 2007 Oct 22;97(8):1035-9. Epub 2007 Sep 25.

41.

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.

Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E, Quirino M, Astone A, Cassano A.

Gastric Cancer. 2007;10(2):104-11. Epub 2007 Jun 25.

PMID:
17577620
42.

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.

Oncology. 2006;70(5):366-77. Epub 2006 Dec 15.

PMID:
17179731
43.

Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.

Barone C, Landriscina M, Quirino M, Basso M, Pozzo C, Schinzari G, Di Leonardo G, D'Argento E, Trigila N, Cassano A.

Br J Cancer. 2007 Jan 15;96(1):21-8. Epub 2006 Dec 12.

44.

Primary renal angiosarcoma: a rare malignancy. A case report and review of the literature.

Leggio L, Addolorato G, Abenavoli L, Ferrulli A, D'Angelo C, Mirijello A, Vonghia L, Schinzari G, Arena V, Perrone L, Citterio F, Bonomo L, Rapaccini GL, Capelli A, Barone C, Gasbarrini G.

Urol Oncol. 2006 Jul-Aug;24(4):307-12. Review.

PMID:
16818182
45.

S100A13, a new marker of angiogenesis in human astrocytic gliomas.

Landriscina M, Schinzari G, Di Leonardo G, Quirino M, Cassano A, D'Argento E, Lauriola L, Scerrati M, Prudovsky I, Barone C.

J Neurooncol. 2006 Dec;80(3):251-9. Epub 2006 Jun 14.

PMID:
16773219
46.

Duodenal metastasis from a primary angiosarcoma of the colon.

Cammarota G, Schinzari G, Larocca LM, Gasbarrini G, Barone C.

Gastrointest Endosc. 2006 Feb;63(2):330; discussion 330. No abstract available.

PMID:
16427950
47.

Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.

Barone C, Cassano A, Pozzo C, D'Ugo D, Schinzari G, Persiani R, Basso M, Brunetti IM, Longo R, Picciocchi A.

Oncology. 2004;67(1):48-53.

PMID:
15459495
48.

Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.

Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C.

Ann Oncol. 2004 Jun;15(6):933-9.

PMID:
15151951
49.

Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.

Barone C, Cassano A, Corsi DC, Pozzo C, Longo R, Schinzari G, Quirino M, Battelli C, Basso M.

Oncology. 2003;64(2):139-45.

PMID:
12566911
50.

Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer.

Cassano A, Bagalà C, Battelli C, Schinzari G, Quirino M, Ratto C, Landriscina M, Barone C.

Anticancer Res. 2002 Jul-Aug;22(4):2179-84.

PMID:
12174901

Supplemental Content

Loading ...
Support Center